Kayne Anderson Rudnick Investment Management LLC Cuts Stock Holdings in Certara, Inc. (NASDAQ:CERT)

Kayne Anderson Rudnick Investment Management LLC lowered its position in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 2.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 784,083 shares of the company's stock after selling 21,701 shares during the quarter. Kayne Anderson Rudnick Investment Management LLC owned approximately 0.49% of Certara worth $8,350,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Blue Trust Inc. lifted its stake in Certara by 20.9% in the 4th quarter. Blue Trust Inc. now owns 4,747 shares of the company's stock worth $56,000 after purchasing an additional 822 shares in the last quarter. Wells Fargo & Company MN lifted its position in Certara by 48.4% during the fourth quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock worth $34,000 after buying an additional 1,047 shares in the last quarter. Bank of Montreal Can boosted its stake in Certara by 9.1% during the fourth quarter. Bank of Montreal Can now owns 19,943 shares of the company's stock worth $212,000 after buying an additional 1,670 shares during the last quarter. O Shaughnessy Asset Management LLC grew its holdings in Certara by 20.5% in the 4th quarter. O Shaughnessy Asset Management LLC now owns 12,943 shares of the company's stock valued at $138,000 after buying an additional 2,202 shares in the last quarter. Finally, Venturi Wealth Management LLC increased its stake in shares of Certara by 839.1% in the 4th quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company's stock worth $30,000 after acquiring an additional 2,509 shares during the last quarter. Hedge funds and other institutional investors own 73.96% of the company's stock.

Certara Trading Up 1.2 %

CERT traded up $0.17 during mid-day trading on Thursday, hitting $14.42. 1,604,076 shares of the stock were exchanged, compared to its average volume of 1,211,316. The firm's fifty day moving average is $11.65 and its two-hundred day moving average is $11.55. Certara, Inc. has a 1-year low of $8.64 and a 1-year high of $17.94. The company has a market cap of $2.33 billion, a PE ratio of -72.10, a PEG ratio of 9.29 and a beta of 1.64. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on CERT shares. TD Cowen began coverage on shares of Certara in a report on Thursday, February 27th. They issued a "buy" rating and a $16.00 price objective for the company. Barclays reduced their price target on shares of Certara from $13.00 to $11.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 10th. William Blair reissued a "market perform" rating on shares of Certara in a research note on Thursday, February 27th. Robert W. Baird increased their price target on Certara from $9.00 to $13.00 and gave the stock a "neutral" rating in a report on Friday, April 11th. Finally, KeyCorp boosted their price objective on shares of Certara from $15.00 to $18.00 and gave the company an "overweight" rating in a report on Wednesday, April 16th. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $15.17.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.